S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth-Reference-Cited by-同舟云学术

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Published:2018-04-13 Issue:28 Volume:9 Page:20075-20088
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Casara Patrick¹,Davidson James²,Claperon Audrey³,Le Toumelin-Braizat Gaëtane³,Vogler Meike⁴,Bruno Alain⁵,Chanrion Maïa³,Lysiak-Auvity Gaëlle³,Le Diguarher Thierry¹,Starck Jérôme-Benoît¹,Chen Ijen²,Whitehead Neil²,Graham Christopher²,Matassova Natalia²,Dokurno Pawel²,Pedder Christopher²,Wang Youzhen⁶,Qiu Shumei⁶,Girard Anne-Marie³,Schneider Emilie³,Gravé Fabienne³,Studeny Aurélie³,Guasconi Ghislaine³,Rocchetti Francesca³,Maïga Sophie⁷,Henlin Jean-Michel¹,Colland Frédéric³,Kraus-Berthier Laurence⁵,Le Gouill Steven⁷,Dyer Martin J.S.⁸,Hubbard Roderick²,Wood Mike²,Amiot Martine⁷,Cohen Gerald M⁹,Hickman John A.³,Morris Erick⁶,Murray James²,Geneste Olivier³

Affiliation:

1. Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France

2. Vernalis (R&D) Ltd., Cambridge, UK

3. Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France

4. Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt, Germany

5. Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France

6. Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA

7. CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France

8. Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK

9. Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, Synthesis, and Evaluation of BCL‐2 Targeting PROTACs;Chemistry – A European Journal;2024-07-25

2. Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy;Cancer Letters;2024-07

3. A novel peptide derived from Zingiber cassumunar rhizomes exhibits anticancer activity against the colon adenocarcinoma cells (Caco-2) via the induction of intrinsic apoptosis signaling;PLOS ONE;2024-06-13

4. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia;Cell Death & Disease;2024-06-12

5. Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges;Acta Pharmaceutica Sinica B;2024-06